1Gotto AM Jr,Grundy SM.Lowering LDL cholesterol:questions from recent meta-analyses and subset analyses of clinical trial data:issues from the interdisciplinary council on reducing the risk for coronary heart disease, Ninth Ciplinary Meeting[C].Circulation,1999,99∶E1-E7.
2Fergus M,Linda B,Robert D,et al.Preclinical and clinical pharmacology of rosuvastatin,a new 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor[J].Am J Cardiol,2001,87∶28B-32B.
3Smith G,Davidson R,Bloor S,et al.Pharmacological properties of ZD4522:a new HMG-CoA reductase inhibitor[J].Atherosclerosis,2000,151∶39.
4Stalker TJ,Lefer AM,Scalia R.A new HMG-CoA reductase inhibitor,rosuvastatin,exerts anti-inflammatory effects on the microvascular endothelium:the role of mevalonic acid[J].Br J Pharmacol,2001,133∶406-412.
5Warwick MJ,Dane AL,Raza A,et al.Single-and mutiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522[J].Atherosclerosis,2000,151∶39.
6Knopp RH.Drug treatment of lipid disorders[J].N Engl J Med,1999,341∶498-511.
7Anders GO,John P,John M,et al.Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia[J].Am J Cardiol,2001,88∶504-508.
8Anders GO.A new statin:a new standard[J].Clin Cardiol,2001,24∶III18-23.
